Page last updated: 2024-08-25

5-hydroxymethylcytosine and Central Nervous System Neoplasm

5-hydroxymethylcytosine has been researched along with Central Nervous System Neoplasm in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Azizgolshani, N; Chen, Y; Christensen, BC; Levy, JJ; Nguyen, LN; Perreard, L; Petersen, CL; Salas, LA1
Chen, CD; Fu, X; Li, J; Li, Q; Li, X; Lin, W; Liu, Y; Wan, Y; Wang, Y; Wang, Z; Xu, Y; Yan, Q; Ye, J; Zhang, F; Zhang, J; Zhang, L; Zhang, M; Zhang, X; Zhang, Z1

Other Studies

2 other study(ies) available for 5-hydroxymethylcytosine and Central Nervous System Neoplasm

ArticleYear
DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker.
    Clinical epigenetics, 2021, 09-19, Volume: 13, Issue:1

    Topics: 5-Methylcytosine; Adolescent; Central Nervous System Neoplasms; Child; Child, Preschool; Female; Gene Expression Regulation; Humans; Male; Neoplasm Staging; Pediatrics

2021
5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas.
    Scientific reports, 2016, Feb-11, Volume: 6

    Topics: 5-Methylcytosine; Adolescent; Adult; Aged; Antibodies; Astrocytoma; Biomarkers, Tumor; Brain; Central Nervous System Neoplasms; Cytosine; Female; Humans; Immunohistochemistry; Isocitrate Dehydrogenase; Ki-67 Antigen; Male; Middle Aged; Mutation; Neoplasm Grading; Prognosis; Spinal Cord; Survival Analysis

2016